Welcome to our dedicated page for Outlook Therapeutics news (Ticker: OTLKW), a resource for investors and traders seeking the latest updates and insights on Outlook Therapeutics stock.
News for OTLKW reflects developments at Outlook Therapeutics, Inc., a biopharmaceutical company concentrated on ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma), an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration (wet AMD). Company news frequently reiterates this focus on enhancing or optimizing the standard of care for bevacizumab in retina indications.
Readers can expect coverage of regulatory milestones, including interactions with the U.S. Food and Drug Administration (FDA) around the Biologics License Application (BLA) for ONS-5010. Recent announcements have described complete response letters, Type A meetings, BLA resubmissions, and FDA acknowledgments of resubmissions as complete, along with associated Prescription Drug User Fee Act (PDUFA) goal dates. These updates provide context on the regulatory pathway for the investigational product in the United States.
The OTLKW news feed also includes information on European commercialization of LYTENAVA™ (bevacizumab gamma), where Outlook Therapeutics reports that the product has received Marketing Authorization from the European Commission and the UK MHRA for the treatment of wet AMD and has been launched commercially in Germany and the UK. News items describe initial sales into distribution channels, early prescribing trends, and efforts to expand into additional European markets, subject to pricing and reimbursement approvals in certain Member States.
Additional news topics include corporate and investor events, such as participation in healthcare conferences, presentations at ophthalmology-focused meetings, and the appointment of senior executives in corporate strategy and business development. Disclosures on stock option grants to new employees as employment inducement awards may also appear. For investors and observers following OTLKW, this news page offers a centralized view of Outlook Therapeutics’ reported clinical, regulatory, commercial, and corporate developments related to its ophthalmic bevacizumab program.
Outlook Therapeutics (OTLK) reported financial results for fiscal year 2024, highlighting the approval of LYTENAVA™ as the first authorized ophthalmic formulation of bevacizumab for wet AMD treatment in the EU and UK. The company plans its first commercial launch in H1 2025, following NICE recommendation. Key developments include upcoming NORSE EIGHT efficacy data expected in January 2025 and BLA resubmission planned for Q1 2025.
Financial results show a net loss of $75.4 million ($4.06 per share) compared to $59.0 million ($4.72 per share) in the previous year. Cash position stands at $14.9 million as of September 30, 2024.
Outlook Therapeutics (OTLK) announced operational streamlining initiatives following internal strategic review. The company will implement a 23% workforce reduction, expecting annual savings of $1.4 million. This decision follows the recent EU and UK regulatory approvals of LYTENAVA™ (bevacizumab gamma) for wet AMD treatment.
LYTENAVA™ received NICE recommendation and has secured 10 years of market exclusivity in the EU and UK as the first authorized ophthalmic formulation of bevacizumab. The company plans to resubmit its BLA application to the FDA in Q1 2025, following the full NORSE EIGHT trial results expected in January 2025.
Outlook Therapeutics (OTLK) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for LYTENAVA™ (bevacizumab gamma) in treating wet age-related macular degeneration (wet AMD). This marks the first positive reimbursement decision worldwide for LYTENAVA™.
The drug, which received regulatory approval in the EU and UK earlier this year, is the first and only approved ophthalmic formulation of bevacizumab for wet AMD treatment in these regions. It has secured 10 years of market exclusivity. The company anticipates its first commercial launch in H1 2025, with potential to benefit approximately 40,000 new wet AMD patients annually in the UK.
The recommendation applies to England and Wales, and follows LYTENAVA™'s Marketing Authorization by the UK MHRA. Outlook Therapeutics has partnered with Cencora for global commercial launch support.
Outlook Therapeutics (OTLK) announced an immediate executive leadership change as Russell Trenary steps down from his position as President and CEO. Lawrence Kenyon, the current Executive Vice President, CFO, and board member, has been appointed as Interim CEO.
The company, which recently received regulatory approval in the EU and UK for LYTENAVA™ (bevacizumab gamma) - the first ophthalmic formulation of bevacizumab for wet AMD treatment - maintains its plans to resubmit the BLA for ONS-5010 in Q1 2025 and commence LYTENAVA™ sales in Europe in H1 2025. The board has initiated a search for a permanent CEO through an executive search firm.
Outlook Therapeutics announced preliminary topline results of NORSE EIGHT trial for ONS-5010 in wet AMD patients. The trial did not meet its pre-specified non-inferiority endpoint at week 8 compared to ranibizumab. The ONS-5010 arm showed +4.2 letter improvement in BCVA versus +6.3 letters for ranibizumab. Despite not meeting the endpoint, the drug demonstrated vision improvement, biologic activity, and favorable safety profile. Final efficacy data is expected in January 2025, with BLA resubmission planned for Q1 2025. The company maintains European and UK marketing authorization for LYTENAVA™, with potential launch in these markets in 2025.
Outlook Therapeutics (OTLK), which recently secured regulatory approval in the EU and UK for its ophthalmic bevacizumab formulation treating wet AMD, announces its participation in the Guggenheim Healthcare Innovation Conference. CEO Russell Trenary will engage in a fireside chat on November 12, 2024, at 2:30 PM ET in Boston, MA. The management team will also conduct one-on-one meetings with qualified investors attending the conference. A live webcast will be available on the company's website, with the replay accessible for 90 days post-event.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, announced that its President and CEO, Russell Trenary, participated in a Virtual Investor CEO Connect segment. The segment, now available for viewing, provided an overview of the company's recent achievements and upcoming milestones. Outlook Therapeutics recently gained regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). The company is working towards becoming the first and only approved ophthalmic formulation of bevacizumab for wet AMD treatment.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, announced its participation in the Virtual Investor Closing Bell Series. Russell Trenary, President and CEO, will present on Thursday, September 19, 2024, at 4:00 PM ET. The event will include a corporate overview, business outlook, and a live Q&A session.
Notably, Outlook Therapeutics recently achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). This milestone highlights the company's progress in the ophthalmology field.
Investors can access the live video webcast on the company's website, with a replay available for 90 days post-event.
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, recently participated in the 2nd Annual Chardan Virtual Ophthalmology Conference Series. The company, which gained regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD), was featured among 8 companies at the event. The conference focused on AMD and diabetes-related ocular diseases.
As part of the virtual event, Outlook Therapeutics' executives Russell Trenary (President and CEO) and Lawrence Kenyon (CFO) participated in a fireside chat hosted by Chardan's Senior Research Analyst, Daniil Gataulin, PhD. A video webcast of this discussion is now available for viewing online.
Outlook Therapeutics (Nasdaq: OTLK) has announced the completion of enrollment for its NORSE EIGHT clinical trial, evaluating ONS-5010 in wet AMD patients. This trial, subject to a Special Protocol Assessment (SPA) agreement with the FDA, is the final anticipated clinical study before the expected resubmission of the company's Biologics License Application (BLA) for ONS-5010.
Key points:
- NORSE EIGHT is a randomized, controlled study comparing ONS-5010 to ranibizumab
- Topline results are expected in Q4 2024
- BLA resubmission is planned for Q1 2025
- The trial aims to address the clinical deficiency identified in the previous Complete Response Letter
If approved by the FDA, Outlook Therapeutics plans to commercialize ONS-5010/LYTENAVA™ (bevacizumab-vikg) directly in the U.S. and is exploring partnering options for Europe and other regions.